Funding for this research was provided by:
Susan G. Komen for the Cure (KG111025)
National Cancer Institute (P30-CA091842, P50-CA196510, T32 CA 009621)
Alvin J Siteman Cancer Center (SIP grant 4053)
Foundation for Barnes-Jewish Hospital
National Institutes of Health (R01CA240983)
Received: 8 March 2019
Accepted: 17 March 2021
First Online: 21 April 2021
: Animal protocols were approved by the Animal Studies Committee of Washington University School of Medicine and were in accord with IACUC guidelines and procedures. The neoantigen DNA vaccine treatment protocol was approved by the Institutional Research Board at Washington University School of Medicine. The patient signed written informed consent documents for the treatment and associated research studies. The research conformed to the principles of the Helsinki Declaration.
: The research protocol and informed consent document allows sharing and publication of the patient’s clinical details and deidentified data, including sharing of raw sequencing data in public repositories such as dbGaP.
: The authors declare that they have no competing interests.